TRINETRA › Sectors › Healthcare
FDC Limited (FDC) — share price, P/E and fundamentals
FDC Limited (NSE: FDC) closed at ₹377.00 on 30 Oct 2026, -13.9% over one year, against a 52-week range of ₹312.95 – ₹473.60.
In the quarter ended 30 Sept 2026 (consolidated, filed 27 Oct 2026) it reported revenue of ₹572 cr and net profit of ₹50 cr, a 8.7% net margin; revenue grew 21.0% and profit grew 71.7% year on year.
On four consecutive filed quarters its trailing P/E is 19.6; since 28 May 2025 its own P/E has ranged from 18.0 to 32.6 (median 27.0), and today's reading is higher than 12% of those 352 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 7.5%, ROCE 9.7%, debt-to-equity 0.00, Piotroski F-score 8 of 9.
Against 66 Healthcare peers on NSE: Net margin higher than 22% of 64 sector peers; PBT margin higher than 19% of 64 sector peers; ROE higher than 16% of 64 sector peers.
Key figures
| Last close | ₹377.00 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | +9.1% / +3.0% / -13.9% |
| 52-week low – high | ₹312.95 – ₹473.60 |
| Market capitalisation | ₹6,138 cr |
| Trailing P/E | 19.6 |
| Price / book | 2.30 |
| EV / EBITDA | 12.7 |
| Earnings yield | 5.1% |
| TTM EPS | ₹19.24 |
| TTM net profit | ₹313 cr |
| Quarter revenue | ₹572 cr |
| Quarter net profit | ₹50 cr |
| Net margin | 8.7% |
| Revenue growth (YoY) | +21.0% |
| Profit growth (YoY) | +71.7% |
| Return on equity | 7.5% |
| ROCE | 9.7% |
| Debt / equity | 0.00 |
| Current ratio | 2.76 |
| Free cash flow | ₹96 cr |
| Piotroski F-score | 8 / 9 |
| Average daily turnover (50 days) | ₹4.0 cr |
Against Healthcare peers
| Metric | FDC | Peer median | Percentile |
|---|---|---|---|
| Net margin | 8.74 | 12.89 | 22 |
| PBT margin | 11.43 | 17.68 | 19 |
| ROE | 7.50 | 13.87 | 16 |
| ROCE | 9.66 | 17.26 | 19 |
| Debt / equity | 0.00 | 0.11 | 12 |
| FCF margin | 7.74 | -0.87 | 60 |
| Cash conversion | 1.38 | 1.25 | 60 |
| Trailing P/E | 19.59 | 43.26 | 8 |
Questions
What is the P/E ratio of FDC Limited?
FDC Limited's trailing P/E is 19.6, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 28 May 2025 its P/E has ranged 18.0–32.6.
What were FDC Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, FDC Limited reported revenue of ₹572 cr and net profit of ₹50 cr (consolidated), filed with the exchange on 27 Oct 2026.
What is FDC Limited's ROE?
Return on equity is 7.5% based on the balance sheet dated 30 Sept 2026.
Does FDC Limited have debt?
Debt-to-equity is 0.00 on the balance sheet dated 30 Sept 2026.
What is FDC's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, FDC traded between ₹312.95 and ₹473.60.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.